CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后复发/难治性大 B 细胞淋巴瘤：当前挑战与治疗选择
英文原题：Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
查看英文原题
Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法可使化学免疫治疗失败后的复发/难治性弥漫大B细胞淋巴瘤（DLBCL）患者获得持久缓解。然而，CAR-T 治疗后仍难治或复发的患者结局较差。研究者已提出多种CAR-T 治疗失败机制，但这类患者的管理仍具挑战。随着CAR-T 治疗逐步前移至DLBCL治疗早期，亟需专门针对CAR-T 治疗后复发患者开展临床试验。双特异性抗体、抗体药物偶联物和下一代CAR-T 疗法等新型免疫疗法近期取得进展，可能为治疗提供新途径。本文综述CAR-T 治疗失败后应用这些药物的现有数据，并提出合理排序使用这些新型药物的框架。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after failure of chemoimmunotherapy.
However, patients who are refractory or relapsing after CAR-T therapy have poor outcomes. Multiple mechanisms of CAR-T therapy failure have been proposed but management of these patients remains a challenge. As CAR-T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR-T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody-drug conjugates and next-generation CAR-T therapies may provide avenues for treatment.
Here we review the available data on using these drugs after failure of CAR-T therapy and provide a framework for the ideal sequencing of these novel agents.
论文信息
- 作者
- Del Toro-Mijares R、Oluwole O、Jayani RV、Kassim AA、Savani BN、Dholaria B
- 第一作者单位
- Escuela de Medicina, Tecnologico de Monterrey, Monterrey, Mexico.Mexico
- 通讯作者单位
- Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.United States
- 文献类型
- 综述
- 期刊
- British journal of haematology2023 Apr
- 原文标识
- PubMed 36709623 · DOI 10.1111/bjh.18656